Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21227887 | 0.94 | CKS1B (0.53) | USP30JAK3BTKSUV39H2CTSK | |
| SCHEMBL7239787 | 0.85 | SYK (0.56) | JAK3BTKSUV39H2CTSKSYK | |
| SCHEMBL952010 | 0.84 | JAK3 (0.58) | JAK3BTKSUV39H2CTSKSYK | |
| SCHEMBL29849700 | 0.84 | SUV39H2 (0.52) | JAK3BTKSUV39H2CTSKSYK | |
| SCHEMBL21227893 | 0.83 | RET (0.44) | USP30JAK3BTKCTSKKDM4D | |
| SCHEMBL1351789 | 0.82 | SYK (0.64) | JAK3BTKSUV39H2SYKPDE10A | |
| SCHEMBL1351791 | 0.82 | SYK (0.64) | JAK3BTKSUV39H2SYKPDE10A | |
| SCHEMBL29689456 | 0.81 | NOTUM (0.56) | JAK3BTKSUV39H2CTSKKDM4D | |
| SCHEMBL8665014 | 0.81 | CTSK (0.57) | JAK3BTKSUV39H2CTSKKDM4D | |
| SCHEMBL1401964 | 0.81 | GPR119 (0.58) | JAK3BTKCTSKSYKPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| EP-3523291-B1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-04-14 | — | — | EP | disclosed |
| WO-2018065768-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP28, USP1 | USP30 1/4885JAK3 2790/4885BTK 3666/4885 |
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | USP30, USP28, USP1 | USP30 1/4885JAK3 2790/4885BTK 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.